Hibiskus Biopharma

Risk score

57

Headquarters

Flag of United States of AmericaUnited States of America

Hibiskus aspires to emerge as the leading company in selective proteasome inhibition by targeting each of the 7 human proteasome catalytic ß subunits with its macrolactam drug candidates. While proteasome suppression is a well-established mechanism for FDA-approved medications, its potential applications in diseases have been relatively limited, predominantly in multiple myeloma, a condition affecting the production of antibodies by blood cells. Since the proteasome is present in all eukaryotic cells, small molecules that specifically target a single proteasome among many (and a sub-catalytic activity) hold potential for numerous pharmaceutical purposes.